These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Countries mull over incentives for developing antibiotics. Anderson T Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638 [No Abstract] [Full Text] [Related]
4. Singapore infectious diseases comes of age. Allen DM Singapore Med J; 1994 Jun; 35(3):314-5. PubMed ID: 7997913 [No Abstract] [Full Text] [Related]
5. Executive summary: global antimicrobial resistance alerts and implications. Alliance for the Prudent Use of Antibiotics Clin Infect Dis; 2005 Aug; 41 Suppl 4():S221-3. PubMed ID: 16032555 [No Abstract] [Full Text] [Related]
6. Changing the focus of infectious diseases to pathogen-specific therapy. Zuger A Clin Infect Dis; 1997 Aug; 25(2):348-50. PubMed ID: 9332552 [No Abstract] [Full Text] [Related]
7. Business aspects of infectious diseases. Tenenbaum MJ; Petrak R Clin Infect Dis; 2002 Feb; 34(3):420. PubMed ID: 11774093 [No Abstract] [Full Text] [Related]
11. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Spellberg B; Sharma P; Rex JH Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569 [No Abstract] [Full Text] [Related]
12. Pay drug companies $1bn for each new antibiotic, says report. Owen J BMJ; 2016 May; 353():i2863. PubMed ID: 27198868 [No Abstract] [Full Text] [Related]
13. The role of new antibiotics for the treatment of infections in the emergency department. Talan DA Ann Emerg Med; 1994 Sep; 24(3):473-89. PubMed ID: 8080145 [TBL] [Abstract][Full Text] [Related]
14. Report urges controversial 'delinkage' to foster new antibiotics. Holmes D Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363 [No Abstract] [Full Text] [Related]
15. Drugs and diagnostic innovations to improve global health. Peeling RW; Nwaka S Infect Dis Clin North Am; 2011 Sep; 25(3):693-705, xi. PubMed ID: 21896368 [TBL] [Abstract][Full Text] [Related]
16. Drug development: Time for teamwork. May M Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427 [No Abstract] [Full Text] [Related]
17. What are the economic barriers of antibiotic R&D and how can we overcome them? Renwick M; Mossialos E Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625 [No Abstract] [Full Text] [Related]
18. The cost of antibiotic treatment for priority infectious syndromes in Paraguay, 2004. Baez E; Dentice MA; Heitmann I Epidemiol Bull; 2005 Jun; 26(2):8-11. PubMed ID: 16578882 [No Abstract] [Full Text] [Related]
19. Report calls for $2bn global fund to kickstart antibiotic development. Wise J BMJ; 2015 May; 350():h2635. PubMed ID: 25975228 [No Abstract] [Full Text] [Related]
20. Models for change in clinical microbiology. Van Eldere J Clin Microbiol Infect; 2000 Aug; 6(8):445-8. PubMed ID: 11168176 [No Abstract] [Full Text] [Related] [Next] [New Search]